Edwards Lifesciences Corporation EW
103.88 USD -1.35 (-1.28%)
Regular-session close
103.88 0.00 0.00%
After hours · Nov 19, 5:15 PM ET
103.49 Day range 105.34
74.66 52-week range 108.00
- YTD
- +21.85%
- 1 year
- +20.76%
News
marketwatch.com Worried investors are paying up for these stocks — some with up to 49% upside, analysts say Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
benzinga.com $1000 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 9.5% on an annualized basis producing an average annual return of 18.23%. Currently, Edwards Lifesciences has a…benzinga.com Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $121 Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $113 to $121.
defenseworld.net Edwards Lifesciences Corporation $EW Stock Bought by Eurizon Capital SGR S.p.A. Eurizon Capital SGR S.p.A. raised its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 19.9% during the third quarter, according to the company in its most recent Form 13F filing…benzinga.com TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $121 TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $117 to $121.
defenseworld.net Edwards Lifesciences Corporation $EW Stake Trimmed by Candriam S.C.A. Candriam S.C.A. reduced its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 44.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund…
marketbeat.com Edwards Lifesciences Q3 Earnings Call Highlights Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.benzinga.com UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118 UBS analyst Patrick Wood maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $118.
benzinga.com JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120 JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $105 to $120.
benzinga.com Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117 Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $117.
benzinga.com Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112 Leerink Partners analyst Mike Kratky maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $101 to $112.
benzinga.com RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $115 RBC Capital analyst Kendall Au maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $110 to $115.
benzinga.com Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120 Barclays analyst Christopher Pasquale maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $110 to $120.
benzinga.com Bernstein Maintains Market Perform on Edwards Lifesciences, Raises Price Target to $106 Bernstein analyst Lee Hambright maintains Edwards Lifesciences (NYSE:EW) with a Market Perform and raises the price target from $99 to $106.
benzinga.com Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $115 Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $101 to $115.
benzinga.com Truist Securities Reiterates Buy on Edwards Lifesciences, Raises Price Target to $118 Truist Securities analyst Richard Newitter reiterates Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $113 to $118.
benzinga.com Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $113 Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $113.
zacks.com Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.benzinga.com Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112 Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $102 to $112.
benzinga.com BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $115 BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $115.
seekingalpha.com Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
benzinga.com Edwards Lifesciences Q3 2026 Earnings Call Transcript Edwards Lifesciences (NYSE:EW) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Edwards Lifesciences Sees Q4 Adj EPS $0.61-$0.69 vs $0.71 Est; Sees Sales $1.670B-$1.750B vs $1.700B Est Edwards Lifesciences (NYSE:EW) is looking for Q4 Adj EPS of $0.61-$0.69 vs $0.71 analyst estimate. sees sales of $1.670 billion-$1.750 billion vs $1.700 billion analyst estimate.
benzinga.com UPDATE: Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 Est; Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est Edwards Lifesciences (NYSE:EW) raises FY2026 Adj EPS guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 analyst estimate. Narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766…
benzinga.com Edwards Lifesciences Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est Edwards Lifesciences (NYSE:EW) narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766 billion vs $6.767 billion estimate.
benzinga.com Edwards Lifesciences Q3 Adj. EPS $0.80 Beats $0.74 Estimate, Sales $1.716B Beat $1.676B Estimate Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.74 by 8.11 percent. This is a 19.4 percent increase over earnings of…
businesswire.com Edwards Lifesciences Reports Third Quarter Results IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72…
benzinga.com This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Wall Street analysts upgraded EW, MSGK, OUST, NVTS; EW, OUST and NVTS also received price-target updates.
247wallst.com Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades…
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.benzinga.com Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113 Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
seekingalpha.com Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints? Heavy AI capex hit free cash flows at Alphabet and Meta, while Microsoft and Amazon faced mounting concerns over compressed margins, search cannibalization, and agentic commerce disruption. With…
seekingalpha.com Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
marketbeat.com Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits Edwards Lifesciences NYSE: EW highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of…benzinga.com Edwards Lifesciences Reports PASCAL System For Tricuspid Repair Shows Superiority Compared To Medical Therapy Alone For Six-Month Primary Endpoint Of CLASP II TR Trial Edwards Lifesciences Corporation (NYSE:EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of…
businesswire.com CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the…benzinga.com Edwards Lifesciences Announces Its PROGRESS Study Demonstrates Transcatheter Aortic Valve Replacement Reduced Composite Endpoint Of Death Or Heart Failure By 30%; Transcatheter Aortic Valve Replacement Lowered Heart Failure Hospitalizations By Over 50% Edwards Lifesciences (NYSE:EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter…
businesswire.com Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial…
zacks.com Edwards' Q3 Earnings on the Horizon: What's in the Cards? Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.
zacks.com Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for…
seekingalpha.com Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives Edwards Lifesciences gets a buy for my initial rating. Strengths come from recent FDA approvals, a niche portfolio serving the cardiology segment, and impressive operating margins and operating cash…
benzinga.com $100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 14.27%. Currently, Edwards Lifesciences has a…
zacks.com Is This the Right Time to Hold EW Stock in Your Portfolio? Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.
businesswire.com FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid…
gurufocus.com Is EW Overvalued? DCF Says Worth $40 On October 21, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a 17.3% increase in price over the past year bu
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
defenseworld.net Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position Birch Hill Investment Advisors LLC lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and…finance.yahoo.com The market could fall 10-12% — stocks to buy and sell now Carter Worth, CEO, Worth Charting warns that overcrowded defensive trades have left the S&P 500 vulnerable to a 10% to 12% ...
biz.chosun.com Busan's Yeonsan Station Sujain Centrio to offer 139 homes for general sale Yeonsan Station Sujain Centrio, an apartment development replacing the Sambo Apartments in Yeonsan-dong, Yeonje District, ...
